Navigation Links
Contrast agent trials in swine
Date:10/16/2007

This release is available in German.

Mammography continues to be the method of choice for the early detection of breast cancer. However, because this technique is not as selective or specific as one would wish, and does not deliver reliable results for every level of tissue density, alternatives are being sought. Near-infrared fluorescence mammography, which works with rays of near-infrared (NIR) light instead of X-rays, is a highly promising techniquealthough effective contrast agents have thus far been lacking. A team led by John V. Frangioni at the Beth Israel Deaconess Medical Center of the Harvard Medical School in Boston, Massachusetts, has developed a contrast agent that makes visible the microcalcifications related to malignant breast tumors. The researchers report in the journal Angewandte Chemie that in validation trials in swine their new contrast agent distinguishes specific calcium salts in soft tissues, as well as depicting bones.

As breast cancer develops, calcium salts are deposited in breast tissue. These microscopic calcium deposits consist mostly of hydroxyapatite, a salt containing calcium and phosphate that is also present in bones.

As the basis of their NIR contrast agent, the researchers chose to use the osteoporosis drug pamidronate, a biphosphonate. Biphosphonates, which are also used for the treatment of bone metastases in breast cancer patients, preferentially bind to bone. Frangioni and his team attached a dye that both absorbs light and fluoresces in the NIR region of the spectrum to a pamidronate derivative. Light in this region of the spectrum penetrates especially well into living tissue without damaging it, and is also easy to detect.

Thanks to a simplified, reliable synthetic route to a new pamidronate derivative developed by Kumar R. Bhushan, the American team has now been able to synthesize large quantities of a contrast agent called Pam800enough to run a trial with large animals. Pigs are particularly well suited to such trials because their organs are of approximately the same size as human organs.

As confirmed by surgical incisions, intravenously administered Pam800 reveals the bones of pigs with very high sensitivity. When hydroxyapatite is injected into the soft tissues, the contrast agent marks only the tiny hydroxyapatite crystals with high selectivity and sensitivity. This could allow it to selectively reveal malignant abnormal tissue. The swine trials demonstrated that the use of real-time NIR fluorescence images even make possible image-guided surgery of the soft tissues and bones.


'/>"/>

Contact: John V. Frangioni
info@frangionilab.org
617-667-0692
John Wiley & Sons, Inc.
Source:Eurekalert

Related biology news :

1. Gadonanotubes greatly outperform existing MRI contrast agents
2. Got inexpensive contrast agent? Milk plays new role in imaging
3. New drug shows promise as powerful anticancer agent
4. To control germs, scientists deploy tiny agents provocateurs
5. Tiny avalanche photodiodes target bioterrorism agents
6. Software agents could help unmask reality of disease clusters
7. Mouse study: New muscle-building agent beats all previous ones
8. Chemical warfare agent detection technology used to treat lung disease
9. Trojan Horse agent halts bone metastasis in mice
10. Failed experiment yields a biocontrol agent that doesnt trigger antibiotic resistance
11. Gallium: A new antibacterial agent?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:8/23/2017)... ... August 23, 2017 , ... NDA Partners Chairman Carl Peck, ... Office of Device Evaluation at the FDA’s Center for Devices and Radiological Health and ... as an Expert Consultant. , Prior to his FDA experience, Dr. Sheets served in ...
(Date:8/22/2017)... ... 2017 , ... One of the biggest opportunities to reduce ... Opioid-dose sparing refers to the reduction of opioid dosage by combining with a ... , The potential for new therapies to replace opioids and/or reduce dosages, however, ...
(Date:8/21/2017)... ... August 21, 2017 , ... MacArthur ... of Hawaii, is pleased to announce the first Delos Wellness Signature™ residence in ... International Realty is working together with listing agent Kelly Allen, R(S) of Carvill ...
(Date:8/21/2017)... ... 21, 2017 , ... Boston Strategic Partners, Inc. (BSP), a ... and Outcomes Research (HEOR) and ‘big data’ to provide a variety of in-depth ... $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP has access to real-world ...
Breaking Biology Technology: